Hualan Biological Engineering Inc. (002007.SZ)

16.56 +0.11 (+0.67%) At close: 03:04PM CST

Hualan Biological Engineering Inc.

No. 1 Hualan Avenue A
Xinxiang 453003
China
86 37 3351 9992
https://www.hualanbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 3,709

Description

Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics in the People's Republic of China. Its blood products comprise human albumin, human immunoglobulin, intravenous human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, human coagulation factor VIII, lyophilized human thrombin for external use, freeze-dried human fibrin glue for surgery, and human fibrinogen. The company's vaccines consist of influenza virus split vaccine, recombinant hepatitis B vaccine, ACYW135 meningococcal polysaccharide vaccine, A H1N1 influenza virus split vaccine, and quadrivalent influenza virus split vaccine. The company has strategic alliance with the Chinese Academy of Sciences, and other scientific research institutes and scientific research companies. The company was founded in 1992 and is based in Xinxiang, the People's Republic of China.

Corporate governance

Hualan Biological Engineering Inc.’s ISS governance QualityScore as of 1 June 2024 is 5. The pillar scores are Audit: 7; Board: 5; Shareholder rights: 5; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.